Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Non-Hodgkin's Lymphoma
Interventions: LBH589; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Nonalcoholic Steatohapatitis
Interventions: Roflumilast, Pioglitazone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Coronado, California • Annapolis, Maryland • Baltimore, Maryland

Conditions: Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions: laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care, therapeutic conventional surgery; Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: afatinib, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 272
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more

Conditions: Prostate Cancer
Interventions: Erlotinib + Bevacizumab; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 12 more

Conditions: Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions: erlotinib hydrochloride, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions: Balstilimab, Biopsy Procedure, Biospecimen Collection, Botensilimab, Radiographic Examination; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 2
States / cities: New Orleans, Louisiana • Houston, Texas

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Erlotinib, Sorafenib; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Palm Springs, California • New York, New York

Conditions: Rheumatoid Arthritis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 20
States / cities: Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more

Conditions: T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia
Interventions: Ruxolitinib, Cladribine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed Solid Tumors, Refractory Solid Tumors
Interventions: Eribulin, Irinotecan, Cefixime; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 13 Years to 30 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Lexington, Kentucky • Dallas, Texas

Conditions: Glioblastoma
Interventions: Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia

Conditions: Covid19 Pneumonia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: The Bronx, New York • Warwick, Rhode Island

Conditions: Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Whole Breast Irradiation; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2040
U.S. locations: 7
States / cities: Gilbert, Arizona • Orlando, Florida • Conroe, Texas + 3 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 66
States / cities: Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions: Alpelisib, Fulvestrant, Aromatase inhibitor; Drug
Lead sponsor: Marina N Sharifi; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more

Conditions: Leukemia, Lymphoma
Interventions: rituximab, epirubicin hydrochloride; Biological · Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intermediate Risk Prostate Cancer
Interventions: Enzalutamide, External Beam Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Dental Anesthesia Efficacy
Interventions: 3% tetracaine HCL with 0.05% oxymetazoline HCL, Lidocaine Injection; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Aging, Endothelial Dysfunction, Cellular Senescence
Interventions: Fisetin, Placebo; Dietary Supplement · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 65 Years and older
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Extranodal Marginal Zone Lymphoma
Interventions: Radiation Therapy; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

Erlotinib for Hepatocellular Carcinoma Chemoprevention

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Enzalutamide + External Beam Rt For Prostate

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia

Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial

Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma